Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors

MANČÍKOVÁ Veronika ŠMÍDA Michal

Year of publication 2021
Type Article in Periodical
Magazine / Source International Journal of Molecular Sciences
MU Faculty or unit

Central European Institute of Technology

Citation
Web https://www.mdpi.com/1422-0067/22/11/5536
Doi http://dx.doi.org/10.3390/ijms22115536
Keywords chimeric antigen receptor; immunotherapy; chronic lymphocytic leukemia; CD19
Description Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info